Paxlovid long covid-19 prevention trial with recruitment in the community in Norway - PANORAMIC-Norway

Helse Bergen HF0 个研究点目标入组 2,000 人开始时间: 2024年5月22日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Symptoms attributable to COVID-19 started within the past 5 days and ongoing., Positive PCR or lateral flow SARS-CoV-2 test. Any positive PCR test or a lateral flow test taken between two days before symptom onset and randomisation qualifies., Age between 18 and 65 years., Participant is able and willing to provide informed consent., Willingness to take a pregnancy test prior to starting study treatment (Participants of childbearing potential).

•Patients that are not able to provide informed consent or comply with all study visits., Use of concomitant medication contraindicated for the treatment of Paxlovid., Pregnant and lactating woman., Participants of childbearing potential (participants who are anatomically and psysiologically capable of becoming pregnant), or have a partner of childbearing potential, not willing to use highly effective contraceptive until 7 days after completing Paxlovid., Patient currently inpatient at hospital., Comorbidity which requires active antiviral treatment as judged by the investigator., Any chronic renal impairment., Any chronic liver disease or liver impairment., Previous randomisation in the PANORAMIC Norway trial., Currently participating in a clinical trial of a therapeutic agent., Currently taking Paxlovid., Known allergy to Paxlovid.

发起方